Oritavancin for Staphylococcus Aureus Infections in Opioid Users

Summary

This will be a pilot single-arm study consisting of 15 participants evaluating the use of oritavancin in the final consolidation phase (last two weeks of treatment) of systemic infections with Staphylococcus aureus (S. aureus) in opioid users. The purpose of this pilot proposal is to collect information for a subsequent large, randomized intervention. Primary endpoints will be 1) Safety and tolerability, and 2) Duration of hospitalization and rate of recurrence.

Timeline

Start

2019-07-01

Primary completion

2022-03-24

Completion

2022-03-24

Drugs

Indications